All manuscripts
Publications TCR T Cells G-Rex®10

CRISPR-Mediated Base Conversion Allows Discriminatory Depletion of Endogenous T Cell Receptors for Enhanced Synthetic Immunity

Published Journal Molecular Therapy - Methods & Clinical Development

Share
13 pages CRISPR-Mediated Base Conversion Allows Discriminatory Depletion of Endogenous T Cell Receptors for Enhanced Synthetic Immunity — Molecular Therapy - Methods & Clinical Development, 2020

Overview

This study utilizes CRISPR base editing to disrupt endogenous TCRs while expressing a hepatitis B-specific recombinant TCR. Cells expanded in G-Rex® showed high purity and enhanced functional avidity. This approach enables the production of potent, off-the-shelf TCR-T cells for treating HCC.

What this paper found

Base editing with a lentiviral vector that carries both an HBV-specific recombinant TCR and a guide RNA against the endogenous TCR beta constant genes removed endogenous TCRs and enriched antigen-specific T cells. After transient delivery of codon-optimized BE3 mRNA and magnetic depletion of residual endogenous TCR-positive cells, products reached over 99% endogenous TCR-negative and 95.9% recombinant TCR-positive in a representative donor. Recombinant TCR surface intensity rose, and edited cells produced more cytokine and killed HepG2 targets faster in impedance and 3D microfluidic assays. Sequencing showed C>T conversion of 37.3% and 24.3% at positions C5 and C6, small and large indels in 8.4% and 8.2% of reads, and under 1% conversion at six predicted off-target sites.

Note: In vitro study using healthy-donor T cells; the authors note that characterization of desirable and unwanted effects of base editors in later therapeutic applications still has to be mapped.

Removal of eTCR enhances the expression of introduced rTCR, reduces the risk of aberrant cross-pairing, and allows discriminatory enrichment of engineered T cells. — Roland Preece, Andrea Pavesi, Soragia Athina Gkazi, Kerstin A. Stegmann, Christos Georgiadis, Zhi Ming Tan, Jia Ying Joey Aw, Mala K. Maini, Antonio Bertoletti, Waseem Qasim, Molecular Therapy - Methods & Clinical Development

Study details

Authors
Roland Preece, Andrea Pavesi, Soragia Athina Gkazi, Kerstin A. Stegmann, Christos Georgiadis, Zhi Ming Tan, Jia Ying Joey Aw, Mala K. Maini, Antonio Bertoletti, Waseem Qasim
Institution
Molecular and Cellular Immunology Unit, UCL Great Ormond Street Institute of Child Health, NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK · Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore · UCL Division of Infection and Immunity, London, UK · Program Emerging Infectious Diseases, Duke-NUS Medical School, Singapore · Singapore Immunology Network (SigN), Agency of Science Technology and Research (A*STAR), Singapore
Journal
Molecular Therapy - Methods & Clinical Development
Year
2020
PMID / PMC
PMID: 33102612 · PMC
G-Rex® model(s)
G-Rex®10
Cell type(s)
TCR T Cells
Application area
Solid tumor
Study phase
Preclinical

How G-Rex® was used

After electroporation of codon-optimized BE3 mRNA on day 4 post-activation and overnight hypothermic culture at 30 °C, the T cells were expanded in G-Rex® 10 flasks (P/N 80040S, Wilson Wolf) for 7 days. Endogenous TCR-expressing cells were then magnetically depleted on day 11, and the cells were cryopreserved on day 14.

Explore related

Full citation

Preece R, Pavesi A, Gkazi SA, et al. CRISPR-Mediated Base Conversion Allows Discriminatory Depletion of Endogenous T Cell Receptors for Enhanced Synthetic Immunity. Mol Ther Methods Clin Dev. 2020;19:149-161.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →